Aduheim

Medicare has proposed limiting coverage of Aduhelm and several prominent groups representing patients and families are pressing to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.

The FDA approves new prescribing instructions for Aduhelm to address confusion over who should get the drug, saying it is appropriate for patients with early or mild Alzheimer’s.